Eledon Pharmaceuticals, Inc. (ELDN)
USD 4.18
(-7.11%)
USD 4.18
(-7.11%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.52 Million | -28.42 Million | -28.91 Million | -15.21 Million | -13.85 Million | -11.89 Million |
| Net Income | -40.32 Million | -87.96 Million | -34.5 Million | -22.81 Million | -16.01 Million | -14.06 Million |
| Depreciation & Amortization | 374 Thousand | 373 Thousand | 195 Thousand | 183 Thousand | 182 Thousand | 11 Thousand |
| Deferred income taxes | -9.89 Million | - | -2.35 Million | -404 Thousand | - | - |
| Stock-based compensation | 6.54 Million | 8.15 Million | 7.9 Million | 3.17 Million | 1.3 Million | 1.54 Million |
| Change in working capital | -4.91 Million | 2.36 Million | -152 Thousand | -180 Thousand | -1.2 Million | 618 Thousand |
| Other non-cash items | 8.69 Million | 48.64 Million | 6.15 Million | 4.82 Million | 1.86 Million | 471 Thousand |
| Investing Cash Flow | -45.28 Million | - | - | 11.03 Million | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | 11.03 Million | - | - |
| Investment purchases | -78.28 Million | - | - | - | - | - |
| Sales/Maturities of investments | 33 Million | - | - | - | - | - |
| Other Investing Activities | -45.28 Thousand | - | - | 11.03 Million | - | - |
| Financing Cash Flow | 33.01 Million | - | -449 Thousand | 109.58 Million | 9.67 Million | 7.56 Million |
| Debt repayment | - | - | - | -25.00 | - | - |
| Dividends payments | - | - | - | -25 Thousand | - | - |
| Common Stock Repurchased | - | - | - | -25.00 | - | - |
| Common Stock Issuance | 33.01 Million | - | -449 Thousand | 9 Million | 9.67 Million | 7.49 Million |
| Other Financing Activities | 33.01 Thousand | - | -450 Thousand | 100.6 Million | 9676.00 | 71 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.6 Million | 2.08 Million | 2.14 Million | -39 Thousand | -1.39 Million | 1.09 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.31 Million | 287 Thousand | -2.29 Million | -141 Thousand | 189 Thousand | -476 Thousand |
| Cash at beginning of period | 56.4 Million | 84.83 Million | 114.19 Million | 8.79 Million | 12.97 Million | 17.3 Million |
| Cash at end of period | 4.61 Million | 56.4 Million | 84.83 Million | 114.19 Million | 8.79 Million | 12.97 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -51.79 Million | -28.42 Million | -29.36 Million | 105.4 Million | -4.18 Million | -4.33 Million |
| Free Cash Flow | -39.52 Million | -28.42 Million | -28.91 Million | -15.21 Million | -13.85 Million | -11.89 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -44.9 Million | -10.29 Million | -9.62 Million | -40.32 Million | -10.34 Million | -9.57 Million |
| Depreciation & Amortization | 97 Thousand | 95 Thousand | 94 Thousand | 374 Thousand | 94 Thousand | 94 Thousand |
| Deferred income taxes | - | - | -889 Thousand | -9.89 Million | 1.25 Million | 1.62 Million |
| Stock-based compensation | 3.06 Million | 1.69 Million | 1.71 Million | 6.54 Million | 1.73 Million | 1.72 Million |
| Change in working capital | 3.16 Million | 265 Thousand | -685 Thousand | -4.91 Million | -3.24 Million | -359 Thousand |
| Other non-cash items | 32.27 Million | 933 Thousand | 265 Thousand | 8.69 Million | -1.73 Million | -1.72 Million |
| Investing Cash Flow | -19.91 Million | 9.78 Million | 10.07 Million | -45.28 Million | -25.02 Million | -30.33 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -36.31 Million | -12.91 Million | -17.92 Million | -78.28 Million | -30.02 Million | -30.33 Million |
| Sales/Maturities of investments | 16.39 Million | 22.7 Million | 28 Million | 33 Million | 5 Million | - |
| Other Investing Activities | -19.91 Million | 9.78 Million | 10.07 Thousand | -45.28 Thousand | -25.02 Thousand | -30.33 Thousand |
| Financing Cash Flow | 48.07 Million | 1000.00 | - | 33.01 Million | - | 33.01 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 48.07 Million | 1000.00 | - | 33.01 Million | - | 33.01 Million |
| Other Financing Activities | 48.07 Million | 1000.00 | -33.01 Thousand | 33.01 Thousand | - | 33.01 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 1.79 Million | 451 Thousand | 1 Million | -2.6 Million | -2 Million | -585 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.36 Million | -186 Thousand | -1.69 Million | -2.31 Million | -1.24 Million | 226 Thousand |
| Cash at beginning of period | 5.65 Million | 4.61 Million | 3.66 Million | 56.4 Million | 40.94 Million | 46.48 Million |
| Cash at end of period | 26.03 Million | 5.65 Million | 4.61 Million | 4.61 Million | 3.66 Million | 40.94 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 20.38 Million | 1.04 Million | 945 Thousand | -51.79 Million | -37.28 Million | -5.53 Million |
| Free Cash Flow | -7.77 Million | -8.74 Million | -9.13 Million | -39.52 Million | -12.25 Million | -8.22 Million |
EASTW-R
PKST
CXC
ACUS
MDP
BIOS